NUVB (Nuvation Bio) Moat Score: 2/10 (As of Jul. 09, 2026)


NUVB Nuvation Bio Inc NUVB
33 GF Score
Price $5.87
! 3 Warning Signs
View Full Analysis

What is Nuvation Bio Moat Score?

Nuvation Bio NUVB +3.53% 33 Moat Score is 2 as of Jul. 09, 2026. GuruFocus rates NUVB with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 1,393 Biotechnology companies, Nuvation Bio ranks better than 58.29% on this metric.

Nuvation Bio has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Nuvation Bio has No Moat: Nuvation Bio Inc lacks significant market leadership or customer loyalty. The company does not have strong intellectual property or patents that provide a competitive edge. Its market presence is limited, and there are no significant regulatory barriers or cost advantages that would suggest a durable competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Nuvation Bio might have No Moat - Very weak/transient advantages.

Nuvation Bio  (NYSE:NUVB) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Nuvation Bio Moat Score Related Terms

NUVB vs VRDN, STOK, ATAI: Moat Score Comparison

For the Biotechnology subindustry, Nuvation Bio's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuvation Bio Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvation Bio's Moat Score distribution charts can be found below:

* The bar in red indicates where Nuvation Bio's Moat Score falls into.


NUVB
33GF Score
Nuvation Bio Inc NUVB
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Nuvation Bio (NUVB) has a Moat Score of 2 as of Jul. 09, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Nuvation Bio ranks #581 out of 1393 companies in the Biotechnology industry, placing it in the top 41.7%.
Is Nuvation Bio's Moat Score too high?
Nuvation Bio's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Nuvation Bio's value of 2 is 0% at this industry median. Based on the distribution chart, Nuvation Bio ranks #581 out of 1393 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nuvation Bio has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Nuvation Bio's Moat Score compare to VRDN and STOK?
According to the Biotechnology industry distribution chart, Nuvation Bio ranks #581 out of 1393 companies for Moat Score. This puts Nuvation Bio in the upper half of its industry. The industry median Moat Score is 2.00. Nuvation Bio's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nuvation Bio's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nuvation Bio's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvation Bio stock overvalued right now?
Nuvation Bio (NUVB) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Nuvation Bio's overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Nuvation Bio (NUVB), the current Moat Score is 2 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nuvation Bio Business Description

Other Exchanges 1E30:Germany
Address 1500 Broadway, Suite 1401, New York, NY, USA, 10036
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
33GF Score

Get the complete analysis for NUVB

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.87
Price